STOCK TITAN

Genetic Technologies Ltd. - GENE STOCK NEWS

Welcome to our dedicated page for Genetic Technologies Ltd. news (Ticker: GENE), a resource for investors and traders seeking the latest updates and insights on Genetic Technologies Ltd. stock.

Genetic Technologies Ltd. (ASX: GTG, NASDAQ: GENE) is a pioneering molecular diagnostics company based in Australia, specializing in genetic testing and reproductive services. The company leverages an extensive array of international patents and allied research activities to explore the profound impact of DNA on health. Its operations span across the Asia Pacific region, offering specialized genetic tests that convert advanced health knowledge into practical applications for humans, animals, and plants.

One of the company's flagship products is BREVAGenplus, a clinically validated risk assessment test that helps in predicting the likelihood of non-hereditary breast cancer. This test has been a game changer in women's health, providing crucial insights that aid physicians in proactive health management. BREVAGenplus is primarily marketed to healthcare professionals, including breast healthcare and imaging centers, obstetricians/gynecologists (OBGYNs), and breast cancer risk assessment specialists.

Genetic Technologies Ltd. offers a broad spectrum of genetic testing services, encompassing medical, animal, forensic, and plant testing. The company's revenue is chiefly derived from markets in Australia and the United States. The organization operates through two primary segments: EasyDNA and GeneType/Corporate.

Recent developments underline the company’s ongoing commitment to innovation and expansion. For example, the company has recently reported the clinical adoption of its groundbreaking geneType Risk Assessment Tests across 12 states in the United States and at a national level in Australia. These tests are designed to provide a comprehensive risk assessment for various diseases, thereby enabling personalized healthcare.

Dr. Carolyn Young, a board-certified Obstetrician and Gynecologist based in Rockville, Maryland, has emphasized the significance of such tests. According to her, misconceptions about breast cancer risks—such as the belief that absence of family history equates to low risk—can be clarified through the use of geneType tests, which identify both hereditary and non-hereditary risks.

The company continues to make strides, as highlighted in their recent announcements. Genetic Technologies Ltd. aims to expand its market reach by launching new comprehensive tests and entering new global markets. These initiatives are part of the company’s strategic efforts to cement its position as a global leader in genomics-based tests in health, wellness, and serious disease.

For further information or inquiries, you can reach out to Simon Morriss, Chief Executive Officer, at investors@genetype.com.

Rhea-AI Summary

Genetic Technologies Limited (NASDAQ: GENE) has announced significant advancements through its acquisition of EasyDNA. The company is expanding its test offerings, now including Carrier Testing and Non-Invasive Prenatal Tests (NIPT) in Europe, targeting the second largest healthcare market. In India, EasyDNA has partnered with stud farms for equine paternity testing. Additionally, a new DNA storage facility has been launched, complying with NATA and CLIA standards. CEO Simon Morriss highlighted these initiatives as critical for ensuring continuous revenue growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.79%
Tags
none
-
Rhea-AI Summary

Genetic Technologies Limited (NASDAQ: GENE) announced the rollout of its geneType Risk Assessment Test across 16 medical practices on Australia's East Coast. This initiative is a part of the GeneType Hub strategy, aiming to enhance primary care by identifying serious diseases early, including cancers and diabetes. Independent models suggest that the test could improve patient outcomes significantly.

With over 212,400 Australians diagnosed with these diseases annually, GENE aims to provide actionable insights for clinicians to better manage chronic health conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.31%
Tags
none
-
Rhea-AI Summary

Genetic Technologies Limited (NASDAQ: GENE) has completed a customizable Budget Impact Model (BIM) for its geneType Breast Cancer Risk Assessment Test, highlighting potential annual savings of US $1.4 billion in breast cancer treatment costs. The BIM emphasizes the need for a comprehensive risk assessment tool, as 85% of breast cancers are sporadic. Key findings indicate an increase in health screening from 69% to 74% and a reduction of interval cancers by 40.5%. This model positions GENE favorably with US Payers, potentially accelerating commercialization and reimbursement processes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
none
Rhea-AI Summary

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) has announced the acquisition of AffinityDNA for £555,000 (approximately US$683,000). This strategic move aims to enhance GENE's direct-to-consumer (DTC) genomics testing portfolio, expanding its presence in key markets such as the US, UK, and Europe. The deal includes acquiring AffinityDNA's assets, which encompass brand identities, distribution rights, and laboratory testing agreements. Furthermore, GENE expects to leverage existing marketing channels and commercial synergies to drive growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
-
Rhea-AI Summary

Genetic Technologies Limited (NASDAQ: GENE) reported a remarkable 475% revenue growth year-to-date for the nine months ending March 31, 2022. The company achieved A$2 million in cash receipts in Q3, primarily from EasyDNA product sales. Key advancements include the launch of the geneType Multi-Risk Test with NATA accreditation and CMS certification, alongside a US patent for the COVID-19 Risk Test. The company maintains a healthy cash balance of A$11.43 million, which provides a 21-month runway for growth initiatives. CEO Simon Morriss highlighted the company's strong position for future commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
none
-
Rhea-AI Summary

Genetic Technologies Limited (NASDAQ: GENE) announced the granting of US Patent No: US 11,257,569 for its geneType COVID-19 Risk Test. This test assesses an individual's risk of severe COVID-19 symptoms requiring hospitalization. CEO Simon Morris emphasized the substantial market potential for this test, which aids in making informed health decisions regarding vaccination and disease management. The test is expected to be useful for unvaccinated individuals, as well as those vaccinated but at high risk. The company aims to enhance health outcomes amid ongoing COVID-19 challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
Rhea-AI Summary

Genetic Technologies Limited (NASDAQ: GENE) announced on February 17, 2022, that its Fitzroy laboratory in Melbourne has achieved dual NATA accreditation and CMS CLIA-certification. This milestone enables the commercial launch of the GeneType Multi-Test in Australia and the USA. This test assesses the risk of six serious diseases including cancers and coronary artery disease, impacting millions annually. The first phase of availability for healthcare professionals began the week of February 21, 2022, with plans to expand its market reach leveraging newly engaged sales teams.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.98%
Tags
none
-
Rhea-AI Summary

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) announced strong Q2 results for FY22, showcasing a cash balance of A$13.5 million and customer receipts of A$1.8 million. The company focuses on genetic testing, launching the Multi-Test for various cancers and diseases, currently awaiting regulatory approval. Notably, a US patent application for the COVID-19 Risk Test has been accepted, with studies confirming its efficacy. The acquisition of EasyDNA enhances their market reach, with operations across 70 websites in 40 countries, poised for growth in the direct-to-consumer genetic testing market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.64%
Tags
none
-
Rhea-AI Summary

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) reported a 112% increase in projected cash receipts to A$1.8 million in 2QFY22, driven by the successful integration of EasyDNA. The company completed submissions for its Multi-Test product to NATA and CMS, expecting regulatory approval soon. As part of its growth strategy, the US patent application for the geneType COVID-19 Risk Test has been accepted, and a cross-validation study confirmed its effectiveness. Strategic partnerships with 1Health and IBX enhance patient distribution networks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
none
Rhea-AI Summary

Genetic Technologies Limited (NASDAQ: GENE) announced that Dr. Erika Spaeth will present at the 2021 San Antonio Breast Cancer Symposium. The company highlighted significant advancements in its geneType Breast Cancer Test, showing better discrimination and calibration compared to traditional models. The new study, which analyzed over 200,000 UK Biobank participants, utilized 313 SNPs to enhance the risk model. The test can effectively identify breast cancer risk in over 85% of women, promoting early detection and better patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
none

FAQ

What is the current stock price of Genetic Technologies Ltd. (GENE)?

The current stock price of Genetic Technologies Ltd. (GENE) is $0.765 as of October 22, 2024.

What is the market cap of Genetic Technologies Ltd. (GENE)?

The market cap of Genetic Technologies Ltd. (GENE) is approximately 3.7M.

What is Genetic Technologies Ltd. known for?

Genetic Technologies Ltd. is known for its pioneering work in molecular diagnostics, offering predictive genetic tests and assessment tools, including the clinically validated BREVAGenplus for non-hereditary breast cancer.

What are the main services offered by Genetic Technologies Ltd.?

The company provides a range of genetic testing services such as medical testing, animal testing, forensic testing, and plant testing.

Where does Genetic Technologies Ltd. generate most of its revenue?

The majority of the company's revenue comes from Australia and the United States.

What is BREVAGenplus?

BREVAGenplus is a clinically validated risk assessment test designed to predict the risk of non-hereditary breast cancer.

Who primarily uses BREVAGenplus?

BREVAGenplus is marketed to healthcare professionals, including those in breast healthcare and imaging centers, obstetricians/gynecologists (OBGYNs), and breast cancer risk assessment specialists.

What are the company's main operating segments?

Genetic Technologies Ltd. operates through two main segments: EasyDNA and GeneType/Corporate.

What recent milestones has Genetic Technologies Ltd. achieved?

The company has recently reported clinical adoption of its geneType Risk Assessment Tests across 12 states in the United States and nationally in Australia.

Who can I contact for more information about Genetic Technologies Ltd.?

You can reach out to Simon Morriss, Chief Executive Officer, at investors@genetype.com for more information.

What is the focus of Genetic Technologies Ltd.'s research?

The company focuses on uncovering the impact of DNA on health through extensive research and an array of international patents.

How does Genetic Technologies Ltd. contribute to women's health?

Genetic Technologies Ltd. contributes to women's health through its predictive testing and assessment tools, particularly the BREVAGenplus test, which helps manage the risk of non-hereditary breast cancer.

Genetic Technologies Ltd.

Nasdaq:GENE

GENE Rankings

GENE Stock Data

3.71M
4.85M
1.87%
0.53%
Diagnostics & Research
Healthcare
Link
United States of America
Prahran